

Truenat test kit gets DCGI approval for Nipah diagnosis

08 September 2021 | News

This is the first kit in India to receive regulatory approval to conduct tests for Nipah



Truenat, an innovative point of care Real-Time PCR platform manufactured by Goa-based Molbio Diagnostics, has received Emergency Use Authorization by the Drugs Controller General of India (DCGI) for their Nipah test.

This is the first kit in India to receive regulatory approval to conduct tests for Nipah. Truenat is an indigenous portable, battery-operated and IoT-enabled point of care RT-PCR platform.

Leveraging the large footprint of Truenat machines deployed across the country for diagnosis of infectious diseases such as TB, COVID-19, Hepatitis, etc., testing for Nipah Virus can now be performed rapidly, on demand and closer to the affected people, resulting in early and fast diagnosis for effective management of the disease and containment of the spread of the virus.

“The R&D work on the Truenat test for Nipah virus was first started in 2018 in collaboration with the National Institute of Virology, Pune (ICMR) to enable the detection of the infectious virus during outbreak situations. The ability to quickly deploy the platform to the point of need and the rapid testing capability makes it a powerful tool in the diagnosis and containment of the Nipah Virus. This collaboration with NIV allows us to react quickly in times of need such as emergencies,” said Dr Chandrasekhar Nair, Director & CTO, Molbio Diagnostics.